Oforta FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 27, 2021.
FDA Approved: Yes (Discontinued) (First approved December 18, 2008)
Brand name: Oforta
Generic name: fludarabine phosphate
Dosage form: Tablets
Treatment for: Chronic Lymphocytic Leukemia
Marketing Status: Discontinued
Oforta (fludarabine phosphate) is an oral nucleoside analogue approved as a single agent for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL).
Development timeline for Oforta
|Dec 19, 2008||Approval Antisoma Receives FDA Approval for Oral Fludarabine, Plans Commercialization Deal to Bring Drug to US Patients|
|Jan 22, 2008||Xanthus Announces Oral Fludarabine NDA Accepted for Review by U.S. FDA|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.